Results 121 to 130 of about 46,198 (239)

Hydroxyurea Toxicity

open access: yes
Hydroxyurea is an antineoplastic agent used alone or in combination with other chemotherapeutic drugs or radiation in the treatment of resistant leukemias and carcinomas of the head and neck.
Khandhar, Paras B, Jinna, Sruthi
core  

Case Report: Late Hypersensitivity Reaction to Hydroxyurea in a Patient With Myeloproliferative Disorder

open access: yesCase Reports in Hematology
Hydroxyurea is a cornerstone therapy for myeloproliferative disorders such as early-stage myelofibrosis. However, rare hypersensitivity reactions can complicate its use and require careful management.
Navkirat Kahlon   +5 more
doaj   +1 more source

Gentiana lutea root aqueous extract mitigates hydroxyurea-induced genotoxicity through antioxidative action and DNA repair: an in vitro study in healthy human peripheral blood mononuclear cells

open access: yesArhiv za Higijenu Rada i Toksikologiju
Hydroxyurea is a chemotherapeutic agent used to treat various conditions, including sickle cell anaemia and myeloproliferative malignancies. However, it has adverse genotoxic effects on normal cells.
Radošević Ksenija   +6 more
doaj   +1 more source

Awareness and Acceptance of Gene Therapy for Sickle Cell Disease Among Individuals From the Eastern Province of Saudi Arabia: A Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background and Aims Public acceptance is important for implementing gene therapy for sickle cell disease (SCD), particularly in regions with a high disease burden. This study assessed self‐perceived knowledge, misconceptions, health literacy, quality of life, and attitudes toward SCD gene therapy among adults from or residing in the Eastern ...
Dana A. Alrezq   +13 more
wiley   +1 more source

Widespread Natural Occurrence of Hydroxyurea in Animals - Fig 1

open access: yes, 2015
A: Fragmentation pattern for derivatized hydroxuyrea (hydroxyurea triTMS). B: Overlaid GC-MS chromatograms of a 10 μg/ml standard of hyroxyurea (maroon), deproteinized liver sample from L.
James S. Ballantyne (830459)   +8 more
core   +1 more source

Genotypic‐Phenotypic Correlations in Non‐HbE β‐Thalassemia Intermedia: A Geographic Systematic Review

open access: yesMolecular Genetics &Genomic Medicine, Volume 14, Issue 11, November 2026.
β‐Thalassemia intermedia exhibits distinct region‐specific molecular patterns shaped by three interacting genetic axes: β‐globin mutation severity, HbF‐inducing modifiers, and α‐globin gene dosage. Mediterranean populations are predominantly mutation‐driven, Middle Eastern populations rely on HbF compensation, and Asian populations are governed by ...
Kavindya Fernando   +2 more
wiley   +1 more source

Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease

open access: yesHaematologica, 2006
Little is known about the pharmacokinetics of hydroxyurea in patients with sickle cell disease (SCD). Our aims were to evaluate bioequivalence between standard hydroxyurea capsules and a new formulation of 1,000 mg coated breakable tablets in adults and ...
M de Montalembert   +9 more
doaj  

Sickle cell anaemia with and without crises: An observational study of pregnancy outcomes

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2264-2272, November 2026.
Summary We assessed the pregnancy outcomes of patients with sickle cell crises. We carried out a retrospective study of 2 698 556 pregnancies in Quebec, Canada between 1989 and 2022. The primary exposure was sickle cell anaemia with crisis during or outside of pregnancy. Outcomes included severe maternal morbidity and other pregnancy complications.
Nathalie Auger   +8 more
wiley   +1 more source

Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome

open access: yes, 2001
The association of lower leg ulcer development and hydroxyurea therapy in patients with myeloproliferative disorders has been reported previously.
Stewart, E. J C   +6 more
core   +1 more source

Phase 3, randomised, placebo‐controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2252-2263, November 2026.
In this trial, conducted in Kenya, Nigeria and Brazil, the resolution of leg ulcers was similar between the voxelotor and placebo arms. In the 12‐week blinded period, the number of sickle cell anaemia with crisis events was higher in the voxelotor arm compared to placebo.
Bernhards Ogutu   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy